Apollo Hospitals Enterprise Ltd.

Apollo Hospitals Enterprise is currently trading at Rs. 1004.05, up by 15.85 points or 1.60 % from its previous closing of Rs. 988.20 on the BSE.

The scrip opened at Rs. 980.00 and has touched a high and low of Rs. 1013.50 and Rs. 975.10 respectively. So far 10353 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1129.00 on 22-Jul-2014 and a 52 week low of Rs. 802.00 on 20-Aug-2013.

Last one week high and low of the scrip stood at Rs. 1012.35 and Rs. 963.00 respectively. The current market cap of the company is Rs. 14004.34 crore.

The promoters holding in the company stood at 34.35% while Institutions and Non-Institutions held 45.57% and 19.34% respectively.

Apollo Hospitals has entered into partnership with Strand Life Sciences to launch genomic tests across its hospitals. The tests would be offered in oncology, cardiovascular, heritable eye diseases and rare genetic disorders. This would be facilitated by Apollo’s subsidiary, Sapine Biosciences.

Moreover, the cost of the tests ranges from Rs 15,000 to Rs 40,000 depending on the nature and specifications. Genomic testing involves analyses of the patient genomes and translating the insights gained to treat patients as part of personalized medicine. Apollo Hospitals is the leading private sector healthcare provider in Asia and owns and manages a network of speciality hospitals and clinics, a chain of Pharmacy retail outlets across the country, and provides Consultancy Services for commissioning and managing the Speciality Hospitals.